Edwards Lifesciences Q4 2024 beats estimates, stock surges
Shares of Edwards Lifesciences Corp. rallied 6.92% to $75.82 Wednesday, on what proved to be an all-around grim trading ...
Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...
Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...
Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company ...
Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...
Morgan Stanley raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $70 and keeps an Equal Weight rating on the shares.
Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.
Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results